InspireMD Closes Public Offering To Save Company From Immanent Demise
This article was originally published in Clinica
InspireMD announced the closing of two separate equity offerings, worth a total of $1.75m on March 31, just a few days after disclosing that an independent audit concluded that the Israeli embolic protection device-maker did not have enough money to survive past May.
You may also be interested in...
Data from the EARLY AF First, Cryo-FIRST and STOP AF trials show cryoablation is a better option than drugs for patients with symptomatic atrial fibrillation.
In this week’s podcast, Marion Webb reviews her interview with Glooko CEO Russ Johannesson and Reed Miller explains how Boston Scientific is restructuring its transcatheter aortic valve business.
The company is recalling all unused Lotus Edge inventory and will stop developing the Lotus platform while shifting resources to support its Acurate neo2 transcatheter aortic valve system. The decision will cost the company up to $300m.